Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $44,040 - $50,760
-3,000 Reduced 26.32%
8,400 $130,000
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $322,910 - $419,195
-24,500 Reduced 68.25%
11,400 $181,000
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $259,160 - $380,380
22,000 Added 158.27%
35,900 $603,000
Q3 2023

Nov 14, 2023

SELL
$11.69 - $15.02 $403,305 - $518,190
-34,500 Reduced 71.28%
13,900 $162,000
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $195,500 - $307,360
-17,000 Reduced 25.99%
48,400 $650,000
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $573,600 - $842,000
40,000 Added 157.48%
65,400 $1.08 Million
Q4 2022

Feb 14, 2023

SELL
$12.25 - $19.5 $193,550 - $308,100
-15,800 Reduced 38.35%
25,400 $472,000
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $168,734 - $370,928
23,900 Added 138.15%
41,200 $529,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.41B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.